原文开头
GENETICALLY engineered immune cells known as CAR T-cells might be able to slow the progress of the neurodegenerative condition amyotrophic lateral sclerosis (ALS) by killing off rogue immune cells in the brain. “It’s not a way to cure the disease,” says Davide Trotti at the Jefferson Weinberg ALS Center in Pennsylvania. “The goal is slowing down the disease.” The life expectancy of people diagnosed with ALS, a form of motor neuron disease, is just two to five years, so slowing the condition’s progression would make a big difference, says Trotti. It is possible that the same approach could help slow other neurodegenerative conditions, too. However, there is evidence that inflammation in the brain contributes to the death of motor neurons. …
摘自《新科学家》(New Scientist)第3583期 · 2026年2月21日,Michael Le Page。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。